Fumapharm (Royalty interest in BG-12 and Fumaderm) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Fumapharm (Royalty interest in BG-12 and Fumaderm) General Information

Description

A portfolio of royalty interests in therapeutic medicines. The portfolio comprises of BG-12, an oral therapeutic medicine for the treatment of relapsing-remitting multiple sclerosis and Fumaderm, a therapeutic medicine for the treatment of moderate to severe plaque psoriasis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Haldenstr. 24a
  • 6006 Lucerne
  • Switzerland
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Royalty Pharma
Corporate Office
  • Haldenstr. 24a
  • 6006 Lucerne
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fumapharm (Royalty interest in BG-12 and Fumaderm) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Fumapharm (Royalty interest in BG-12 and Fumaderm)‘s full profile, request access.

Request a free trial

Fumapharm (Royalty interest in BG-12 and Fumaderm) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Fumapharm (Royalty interest in BG-12 and Fumaderm)‘s full profile, request access.

Request a free trial

Fumapharm (Royalty interest in BG-12 and Fumaderm) FAQs

  • Where is Fumapharm (Royalty interest in BG-12 and Fumaderm) headquartered?

    Fumapharm (Royalty interest in BG-12 and Fumaderm) is headquartered in Lucerne, Switzerland.

  • What industry is Fumapharm (Royalty interest in BG-12 and Fumaderm) in?

    Fumapharm (Royalty interest in BG-12 and Fumaderm)’s primary industry is Buildings and Property.

  • Is Fumapharm (Royalty interest in BG-12 and Fumaderm) a private or public company?

    Fumapharm (Royalty interest in BG-12 and Fumaderm) is a Private company.

  • What is the current valuation of Fumapharm (Royalty interest in BG-12 and Fumaderm)?

    The current valuation of Fumapharm (Royalty interest in BG-12 and Fumaderm) is 00000.

  • What is Fumapharm (Royalty interest in BG-12 and Fumaderm)’s current revenue?

    The current revenue for Fumapharm (Royalty interest in BG-12 and Fumaderm) is 000000.

  • Who are Fumapharm (Royalty interest in BG-12 and Fumaderm)’s investors?

    Fumapharm has invested in Fumapharm (Royalty interest in BG-12 and Fumaderm).

  • When was Fumapharm (Royalty interest in BG-12 and Fumaderm) acquired?

    Fumapharm (Royalty interest in BG-12 and Fumaderm) was acquired on 02-May-2012.

  • Who acquired Fumapharm (Royalty interest in BG-12 and Fumaderm)?

    Fumapharm (Royalty interest in BG-12 and Fumaderm) was acquired by Royalty Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »